miR-31a-5p promotes postnatal cardiomyocyte proliferation by targeting RhoBTB1.
- Author:
Junjie XIAO
1
;
Hui LIU
;
Dragos CRETOIU
;
Daniela Oana TOADER
;
Nicolae SUCIU
;
Jing SHI
;
Shutong SHEN
;
Yihua BEI
;
Joost PG SLUIJTER
;
Saumya DAS
;
Xiangqing KONG
;
Xinli LI
Author Information
- Publication Type:Original Article
- MeSH: Animals; Cell Count; MicroRNAs; Myocardium; Myocytes, Cardiac*; Negotiating; Proliferating Cell Nuclear Antigen; Rats
- From:Experimental & Molecular Medicine 2017;49(10):e386-
- CountryRepublic of Korea
- Language:English
- Abstract: A limited number of microRNAs (miRNAs, miRs) have been reported to control postnatal cardiomyocyte proliferation, but their strong regulatory effects suggest a possible therapeutic approach to stimulate regenerative capacity in the diseased myocardium. This study aimed to investigate the miRNAs responsible for postnatal cardiomyocyte proliferation and their downstream targets. Here, we compared miRNA profiles in cardiomyocytes between postnatal day 0 (P0) and day 10 (P10) using miRNA arrays, and found that 21 miRNAs were upregulated at P10, whereas 11 were downregulated. Among them, miR-31a-5p was identified as being able to promote cardiomyocyte proliferation as determined by proliferating cell nuclear antigen (PCNA) expression, double immunofluorescent labeling for α-actinin and 5-ethynyl-2-deoxyuridine (EdU) or Ki-67, and cell number counting, whereas miR-31a-5p inhibition could reduce their levels. RhoBTB1 was identified as a target gene of miR-31a-5p, mediating the regulatory effect of miR-31a-5p in cardiomyocyte proliferation. Importantly, neonatal rats injected with a miR-31a-5p antagomir at day 0 for three consecutive days exhibited reduced expression of markers of cardiomyocyte proliferation including PCNA expression and double immunofluorescent labeling for α-actinin and EdU, Ki-67 or phospho-histone-H3. In conclusion, miR-31a-5p controls postnatal cardiomyocyte proliferation by targeting RhoBTB1, and increasing miR-31a-5p level might be a novel therapeutic strategy for enhancing cardiac reparative processes.
